GLP1R and metabolic dysfunction-associated steatotic liver disease: Lule et al. [43] revealed new hypothetical mechanisms for a protective role of Exenatide, a widely used GLP-1 receptor agonist, for the amelioration of IR-induced inflammation and non-alcoholic fatty liver disease (NAFLD).